The stock of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) is a huge mover today! About 72,232 shares traded hands. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 30.67% since April 22, 2016 and is downtrending. It has underperformed by 36.08% the S&P500.
The move comes after 8 months positive chart setup for the $4.74B company. It was reported on Nov, 25 by Barchart.com. We have $114.70 PT which if reached, will make NYSE:TARO worth $331.80M more.
Analysts await Taro Pharmaceutical Industries Ltd. (NYSE:TARO) to report earnings on February, 8.
According to Zacks Investment Research, “Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals.”
More notable recent Taro Pharmaceutical Industries Ltd. (NYSE:TARO) news were published by: Prnewswire.com which released: “Shareholder Class Action Filed Against Taro Pharmaceutical Industries Ltd. – TARO” on November 15, 2016, also Businesswire.com with their article: “Taro Announces Appointment of New CEO and New Board Member Nominations” published on November 22, 2016, Forbes.com published: “RSI Alert: Taro Pharmaceutical Industries (TARO) Now Oversold” on August 24, 2016. More interesting news about Taro Pharmaceutical Industries Ltd. (NYSE:TARO) were released by: Globenewswire.com and their article: “TARO LOSS ALERT: Rosen Law Reminds Taro Pharmaceutical Industries Ltd …” published on November 16, 2016 as well as Nasdaq.com‘s news article titled: “Taro Pharmaceutical Industries Enters Oversold Territory (TARO)” with publication date: November 03, 2016.
TARO Company Profile
Taro Pharmaceutical Industries Ltd. (Taro), incorporated on June 3, 1959, is a science pharmaceutical company. The Firm develops, makes and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and makes active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company’s primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.